A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Boston Scientific Corporation
Astellas Pharma Inc
Astellas Pharma Inc
AstraZeneca
Daiichi Sankyo
EMD Serono
TScan Therapeutics, Inc.
Immuneering Corporation
Nuvectis Pharma, Inc.
Carisma Therapeutics Inc
Nimbus Therapeutics
AO GENERIUM
Adaptimmune